Blog
What is new, and what the evidence says
Every post cites its sources and links to the compound profiles it discusses. Educational only, no dosing.
Metabolic · 8 min · Sep 9, 2026
Tesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. The 2008 Lancet Phase 2 (203 patients, 24 weeks, about 10 percent weight loss at the top dose), the Mexican Phase 3 and stalled COFEPRIS application, the heart-rate signal that led to a beta-blocker combination, how it compares with phentermine, and why it ends up in peptide storefronts.
Longevity · 12 min · Sep 9, 2026
Peptides for Longevity: What the Evidence Actually Shows in 2026
A pillar review of every peptide and peptide-adjacent compound sold for aging, epitalon, thymalin, MOTS-c, humanin, SS-31, GHK-Cu, klotho, FOXO4-DRI, the growth-hormone axis, GLP-1 drugs, senolytics and rapamycin, with the best human study, the animal data and the regulatory status of each in one table.
Healing & Recovery · 9 min · Sep 9, 2026
Peptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
What the human trials say about joint pain candidates: lorecivivint (NDA under FDA review since January 2026 after two Phase 3 misses on pain), oral collagen peptides (three small RCTs), pentosan polysulfate (a 538-patient Phase 3 reading out in 2027), hyaluronic acid injections (89 trials, tiny effect), and the animal-only pair BPC-157 and TB-500.
Healing & Recovery · 8 min · Sep 9, 2026
Peptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
Five peptides sold or studied for the gut, ranked by what has actually been tested in people: teduglutide (approved), larazotide (a positive Phase 2b, then a Phase 3 stopped for futility in 2022), BPC-157 and KPV (animal data only, advisory votes in July 2026) and pentadeca arginate (no studies at all).
Metabolic · 10 min · Sep 9, 2026
Oral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
The three approved GLP-1 pills, why a peptide pill needs an empty stomach and a small molecule does not, the trial numbers behind each approval (OASIS 4, ATTAIN-1, PIONEER), the boxed warning they all carry, and the pipeline: aleniglipron, elecoglipron, HRS-7535, and the drug Pfizer walked away from.
Metabolic · 9 min · Sep 9, 2026
MariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
How Amgen's antibody-peptide conjugate works, why it blocks GIP when tirzepatide activates it, what the 592-person Phase 2 in NEJM showed at 52 weeks, what the second-year maintenance data mean, the MARITIME Phase 3 program, the gut-tolerability problem and the dose-escalation fix, and where Pfizer's berobenatide fits as the other monthly.
Metabolic · 9 min · Sep 9, 2026
Cagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
What amylin does, what cagrilintide showed on its own in its 2021 Lancet trial, what REDEFINE 1, 2 and 4 showed for CagriSema, where the December 2025 FDA filing stands, how eloralintide, petrelintide and AZD6234 compare, and why the 'cagrilintide plus retatrutide' stack has no trial behind it.
Longevity · 9 min · Sep 9, 2026
Senolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
Every human senolytic trial that has read out as of September 2026: Kirkland's dasatinib plus quercetin pilots in lung fibrosis and diabetic kidney disease, the still-unfinished fisetin trials, foselutoclax in the eye, RLS-1496 on skin, and why the capsules sold as senolytics have nothing to do with any of it.
Research · 9 min · Sep 9, 2026
Peptides for Hair Growth: GHK-Cu, PTD-DBM and the PP405 Phase 2a Results
What the evidence tiers actually are for the hair-growth peptides sold online: GHK-Cu (animal and cosmetic data), AHK-Cu (in vitro only), PTD-DBM (one 2017 mouse study), and PP405, the topical small molecule whose Phase 2a trial reported 31 percent of men gaining more than 20 percent hair density at 8 weeks, set against 48-week minoxidil and 1-year finasteride trials.
Research · 9 min · Sep 9, 2026
Peptides for Sleep: DSIP, Epitalon and Pinealon Against the Evidence
What the 1980s and 1992 DSIP insomnia trials actually found, why the FDA advisory committee voted against DSIP (emideltide) and for Epitalon in July 2026, what Khavinson's single-lab melatonin data can and cannot support, how ghrelin and GHRH change slow-wave sleep, and how all of it compares with approved insomnia drugs.
Longevity · 9 min · Sep 9, 2026
The Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
An educational review of the human rapamycin evidence: the 48-week PEARL trial (Aging, 2025), the finding that compounded rapamycin delivers about 31 percent of the blood level of commercial tablets, the 333-person user survey, Blagosklonny's case for weekly schedules, the mouse lifespan data, and why no human lifespan benefit has been shown.
Safety · 9 min · Sep 9, 2026
Peptide Side Effects by Class: What Is Documented, What Is Anecdotal
A class-by-class table separating adverse events recorded in controlled trials and FDA labels (GLP-1 drugs, MK-677, elamipretide, bremelanotide) from the anecdotal reports that fill forums for BPC-157, TB-500, copper peptides and nootropic peptides.
Safety · 8 min · Sep 8, 2026
How to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
What each field on a peptide COA means, what a purity percentage does and does not tell you, how to verify a Janoshik report, and the red flags the FDA's own 2026 review found in market products. No vendor recommendations.
Metabolic · 7 min · Sep 8, 2026
SLU-PP-332 and 5-Amino-1MQ: Two 'Peptides' That Are Not Peptides, and What the Mouse Data Actually Show
Both are sold next to peptides and searched as peptides. Both are small molecules with animal data only. What SLU-PP-332 does to muscle in mice and why its heart safety is unknown; what 5-amino-1MQ does to fat cells and why it is on Amazon without a single human trial.
Metabolic · 9 min · Sep 8, 2026
Retatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
One table with the headline weight-loss numbers, their trial names and their durations, so a 36-week Phase 2 result is never compared to an 80-week Phase 3 result by accident. Covers retatrutide, tirzepatide, semaglutide, CagriSema, MariTide, amycretin, eloralintide, enicepatide and the oral drugs.
Longevity · 8 min · Sep 8, 2026
NMN vs NR vs NAD+: The 2026 Head-to-Head Human Trials, and Who Funded the Comparisons
Two human trials in 2026 finally compared NMN and NR directly and reached different conclusions. What each measured, what neither showed, why Amazon pulled NMN, and how to read a comparison written by a company that sells one of them.
Research · 11 min · Sep 8, 2026
New Peptides and Longevity Compounds in 2026: What Is Actually New, What Is Newly Legal, and What Is Just New to Vendors
A sorted guide to the 68 compounds we added in September 2026: the pharma pipeline with trial numbers, the community-trending products with their evidence tier, and the ones with safety flags, including FLGR-242, RTR242, klotho, eloralintide and berobenatide.
Healing & Recovery · 8 min · Sep 8, 2026
GLOW vs KLOW vs Wolverine: What Is in Each Stack and What the Evidence Says, Ingredient by Ingredient
The three most-searched peptide blends of 2026 explained: exactly what is in Wolverine, GLOW and KLOW, the evidence tier for each ingredient, the stability problem nobody mentions, and why no study has ever tested any of the blends.
Longevity · 7 min · Sep 8, 2026
SS-31 and Elamipretide: What the Forzinity Approval Does and Does Not Mean
Elamipretide (SS-31) became the first FDA-approved mitochondria-targeted peptide in September 2025, for one rare disease. What the approval covers, what the trials showed, and why it says nothing about the research-grade SS-31 sold online.
Metabolic · 7 min · Sep 8, 2026
MOTS-c: The Mouse Data, the One Human Trial, and the 7 to 5 FDA Vote
What MOTS-c is, why it is called an exercise mimetic, why no completed human trial exists as of 2026, what the Phase 2a in prediabetes will measure, and what the July 2026 advisory vote does and does not change.
Longevity · 8 min · Sep 8, 2026
Klotho Explained: Protein, Peptide, Gene Therapy or Supplement?
What alpha-klotho is, what the mouse and monkey studies actually showed, the two human programs that started in 2026, and why the 'klotho peptide' sold online is not the molecule in any of those studies.
Regulation · 9 min · Sep 8, 2026
FDA Peptide Status in 2026: The Category 2 Removals, the July Votes, and What Actually Changed
A dated tracker of where BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax and DSIP stand with the FDA after the April 2026 list change and the July 23 to 24 advisory committee votes, with links to every source document.